Skip to main content
. Author manuscript; available in PMC: 2011 May 1.
Published in final edited form as: Neuromuscul Disord. 2010 Jul 15;20(11):753–760. doi: 10.1016/j.nmd.2010.06.016

Fig. 6.

Fig. 6

Subcutaneous injection of Debio-025 reduces pathology in mdx mice better than prednisone. (A, B) Muscle weight (MW) normalized to tibia length (TL) for quadriceps and gastrocnemius treated with vehicle, prednisone (1 mg/kg/day), Debio-025 (50 mg/kg/day), or prednisone/Debio-025. (C, D) Percentage of fibers containing centrally located nuclei from quadriceps and gastrocnemius in the indicated treatment groups. (E, F) Percentage of myofibers with surfaces areas <100 μm2 from quadriceps and gastrocnemius in the indicated treatment groups. (G, H) Quantification of fibrotic area from trichrome stained sections of quadriceps and gastrocnemius in the indicated treatment groups. *P < 0.05 vs Wt vehicle; †P < 0.05 vs mdx vehicle; #P < 0.05 vs mdx prednisone. The key in A also applies to B–H. The error bars represent s.e.m. Five mdx and 3 Wt mice were assessed here for each panel.